I’ve spent the last several months at life science conferences, dinners, and
networking events, talking to founders, CEOs, and investors. And I keep
hearing the same thing, just in different rooms.
Investors are stuck with Portfolios they can’t exit. Which means less fresh capital, slower deal flow, and no rescue rounds for companies that have been hoping funding would paper over weak sales.
That’s not a strategy. That’s a waiting game most companies can’t afford to play.
For CROs, research tools companies, and life science services,
the answer isn’t to hold your breath. It’s to get brutally focused.
Focus on what customers actually need right now. On the segments that can buy. On the channels producing real opportunities. On the activities — people, programs, territories, campaigns — that tie back to measurable revenue.
Less is better when less is pointed at growth.
The hard questions boards and leadership teams should be asking:
— Where are we spending money that isn’t generating revenue?
— Which products deserve more investment, and which should we quietly walk away from?
— Which markets are we chasing out of habit rather than results?
— What does the data actually say about our salespeople, campaigns, and customer segments?
— Where do we need to realign: budget, people, execution?
These aren’t comfortable conversations. But they’re the right ones.
At PSG Life Sciences, this is exactly what we help companies work through,
assessing what’s working, cutting what isn’t, and realigning toward growth.
Capital may be tight, but Execution cannot be.
#LifeSciences #Biotech #CRO #Commercialization
#SalesStrategy #RevenueGrowth